MARKET

VXRT

VXRT

VAXART
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.25
-0.39
-6.91%
After Hours: 5.30 +0.05 +0.95% 19:55 10/26 EDT
OPEN
5.54
PREV CLOSE
5.64
HIGH
5.55
LOW
5.13
VOLUME
5.98M
TURNOVER
--
52 WEEK HIGH
17.49
52 WEEK LOW
0.2660
MARKET CAP
574.71M
P/E (TTM)
-8.7690
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Vaxart: A Strong Buy For Their Oral Tablet Covid-19 Vaccine
Vaxart, an oral tablet vaccine developer, has initiated and dosed the first participants in their phase 1 trial for COVID-19.Although later in development, Vaxart's oral tablet vaccine presents significant advantages in manufacture, distribution, and ease-of-administration that may contribute to a much more successful vaccination campaign, if successfully developed.Vaxart is a Buy for investors who have the right risk tolerance for a highly speculative, high risk and higher reward investment opportunity.
Seekingalpha · 3d ago
Vaxart poised to continue post-stock sales deal selloff
Vaxart (VXRT) is down 6% premarket on increased volume. Shares have sold off over 20% since last week after it disclosed a $250M at-the-market stock sales deal with Jefferies.Shares are down 65% since touching $17.49 on
Seekingalpha · 10/19 13:21
American Equity Investment Life, Vaxart leads premarket losers' pack
The9 (NCTY) -18%.Emerson Radio (MSN) -12%.American Equity Investment Life (AEL) -9% as Citi raises Brookfield Asset Management as AEL deal opens growth plan.ReWalk Robotics (RWLK) -10% on appointment of Randel Richner to the Board of Directors,
Seekingalpha · 10/19 12:12
Vaxart: An Alternative Opportunity in the COVID-19 Vaccine Landscape
On Tuesday, vaccine specialist Vaxart (VXRT) announced it has dosed the first subject in the Phase 1 study of VXA-CoV2-1, the company’s oral, room-temperature stable COVID-19 vaccine candidate.After the vaccine impressed in preclinical models, it is a timely announcement from Vaxart. While the small biotech is significantly behind other, mostly bigger competitors in its Covid-19 vaccine program, as recent events have shown, bringing to market a viable solution is far from hassle free.Earlier this week, Johnson & Johnson halted its Covid-19 vaccine candidate’s Phase 3 study due to a participant’s unexplained illness. That event was swiftly followed by Eli Lily pausing enrollment for its Covid-19 treatment program due to safety concerns.For FBR Riley analyst Mayank Mamtani, the bigger players’ struggles highlight the alternative opportunity Vaxart presents for investors.“As the COVID-19 cases continue to spike WW and leading programs from J&J and AZN experience speedbumps with late-stage development, albeit temporary, it is becoming increasingly important to have multiple shots on goal in the C-19 vaccine landscape and recommend investors diversify positions, including with alternative modalities, e.g., VXRT’s oral candidate, which not only have the potential to be self-administered but are also room-temperature stable and rapidly scalable, conferring significant advantages with respect to stockpiling and distribution, particularly relevant in non-western economies with limited healthcare resources,“ Mamtani commented.Vaxart stock has experienced a roller coaster ride in 2020. Despite being up by 1637% year-to-date, the share price has actually retreated by over 60% since the July yearly highs. Mamtani believes that in addition to the pullback, its “valuation disconnect relative to more advanced C-19 vaccine peers, presents an additional compelling buying opportunity.”To this end, Mamtani rates VXRT a Buy along with a $22 price target. Investors could be pocketing a massive 262% gain, should his thesis play out over the next year. (To watch Mamtani’s track record, click here)Overall, only one other analyst is currently keeping a tab on Vaxart’s progress, also recommending the stock a Buy. Vaxart, therefore, has a Moderate Buy consensus rating backed with a $19.50 average price target. The figure suggests potential upside of 220% in the year ahead. (See VXRT stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 10/17 01:28
'U.S. Investigates Vaxart's Claims Related to Covid-19 Vaccine' -New York Times Report
https://www.nytimes.com/2020/10/15/business/vaxart-covid-coronavirus-vaccine.html?smid=tw-nytimesbusiness&smtyp=cur
Benzinga · 10/15 17:34
Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
Vaxart (VXRT) doses the first subject in an early-stage study of its oral coronavirus vaccine candidate VXA-CoV2-1. Stock rises.
Zacks · 10/14 15:26
Covid Report: Moderna Gets Key Ruling In Europe; Vaxart Tablet Passes 'Hamster Challenge'
Investor's Business Daily · 10/14 14:41
Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.
Zacks · 10/14 14:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VXRT. Analyze the recent business situations of VAXART through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VXRT stock price target is 19.67 with a high estimate of 22.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 97
Institutional Holdings: 20.56M
% Owned: 18.78%
Shares Outstanding: 109.47M
TypeInstitutionsShares
Increased
15
5.47M
New
64
10.68M
Decreased
7
26.96M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Director
Wouter Latour
Chief Executive Officer/Chief Financial Officer/Director
Andrei Floroiu
Chief Accounting Officer/Vice President/Controller
Margaret Echerd
Chief Scientific Officer
Sean Tucker
Other
David Taylor
Lead Director/Independent Director
Robert Yedid
Director
Steven Boyd
Director
Keith Maher
Independent Director
Todd Davis
Independent Director
Michael Finney
Director
I. Keith Maher
Independent Director
Anne VanLent
Independent Director
Bob Yedid
Independent Director
Karen Wilson
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
10/25/2012
Dividend USD 1.108
11/09/2012
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VXRT
Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Vaxart Inc stock information, including NASDAQ:VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.